1.
Am J Health Syst Pharm
; 73(11): 750-4, 2016 Jun 01.
Article
in English
| MEDLINE
| ID: mdl-27208059
Subject(s)
Anti-Retroviral Agents/administration & dosage , Anti-Retroviral Agents/blood , Deglutition , Drug Compounding/methods , Administration, Oral , Aged , Anti-Retroviral Agents/chemistry , Dosage Forms , HIV Infections/blood , HIV Infections/diagnosis , HIV Infections/drug therapy , Humans , Infusions, Intravenous , Male
2.
AIDS
; 25(11): 1437-9, 2011 Jul 17.
Article
in English
| MEDLINE
| ID: mdl-21712657
Subject(s)
Adenine/analogs & derivatives , Blood-Brain Barrier/drug effects , Deoxycytidine/analogs & derivatives , HIV Infections/drug therapy , Organophosphonates/adverse effects , Adenine/adverse effects , Adult , Blood-Brain Barrier/injuries , Deoxycytidine/adverse effects , Emtricitabine , Female , HIV Infections/cerebrospinal fluid , Humans , Male , Middle Aged , Pilot Projects , Tenofovir
3.
Antivir Ther
; 9(5): 811-7, 2004 Oct.
Article
in English
| MEDLINE
| ID: mdl-15535419
ABSTRACT
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
